Effects of atorvastatin metabolites on induction of drug‐metabolizing enzymes and membrane transporters through human pregnane X receptor

BACKGROUND AND PURPOSE Atorvastatin metabolites differ in their potential for drug interaction because of differential inhibition of drug‐metabolizing enzymes and transporters. We here investigate whether they exert differential effects on the induction of these genes via activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR).

[1]  J. Xu,et al.  DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.

[2]  J. Shyy,et al.  Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo , 2006, Circulation.

[3]  Julia Qiu,et al.  Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin , 2004, Pharmaceutical Research.

[4]  Ute Hofmann,et al.  Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes , 2010, Drug Metabolism and Disposition.

[5]  D. Corella,et al.  Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. , 2001, Atherosclerosis.

[6]  Kaoru Kobayashi,et al.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells , 2005, Pharmacogenetics and genomics.

[7]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[8]  H. Lennernäs.  Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.

[9]  Tao Chen,et al.  Multi-species analyses of direct activators of the constitutive androstane receptor. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[10]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[11]  D. Moore,et al.  Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. , 2000, Molecular cell.

[12]  N. Plant,et al.  The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  Thomas S Weiss,et al.  Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. , 2003, Journal of hepatology.

[14]  M. Hirata,et al.  Statin regulation of CYP3A4 and CYP3A5 expression. , 2009, Pharmacogenomics.

[15]  L. A. Lim,et al.  Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. , 2010, International journal of clinical pharmacology and therapeutics.

[16]  D. Hardie,et al.  AMP-activated Protein Kinase Mediates Phenobarbital Induction of CYP2B Gene Expression in Hepatocytes and a Newly Derived Human Hepatoma Cell Line* , 2005, Journal of Biological Chemistry.

[17]  Oliver Burk,et al.  Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor , 2005, Molecular Pharmacology.

[18]  V. Trezza,et al.  Xenosensors CAR and PXR at work: impact on statin metabolism. , 2011, Current drug metabolism.

[19]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[20]  M. Eichelbaum,et al.  Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor , 2004, Nuclear receptor.

[21]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[22]  P. Kollman,et al.  Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[23]  M. Stoner,et al.  Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. , 2010, Chemico-biological interactions.

[24]  A. Poli.  Atorvastatin , 2012, Drugs.

[25]  J. Pascussi,et al.  Drug Interaction Potential of 2-((3,4-Dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the Novel Nonstatin-Type Cholesterol-Lowering Agent , 2009, Drug Metabolism and Disposition.

[26]  P. Ascenzi,et al.  Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. , 2009, Molecular aspects of medicine.

[27]  T. Sakaeda,et al.  Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport , 2005, Pharmaceutical Research.

[28]  K. Kivistö,et al.  Rhabdomyolysis in a patient receiving atorvastatin and fluconazole , 2005, European Journal of Clinical Pharmacology.

[29]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[30]  M. Hirai,et al.  Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  B. H. Stewart,et al.  Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter , 2000, Pharmaceutical Research.

[32]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[33]  Kosuke Saito,et al.  Ligand-dependent assembly of pregnane X receptor, constitutive androstane receptor and liver X receptor is applicable to identify ligands. , 2010, Drug metabolism letters.

[34]  Peter-Tobias Stoll,et al.  Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany , 2004, Cell and Tissue Banking.

[35]  Yoshiro Saito,et al.  Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. , 2004, Molecular pharmacology.

[36]  U. Brinkmann,et al.  Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[37]  Oliver Burk,et al.  Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin* , 2001, The Journal of Biological Chemistry.

[38]  Hongbing Wang,et al.  Activation of xenobiotic receptors: driving into the nucleus , 2010, Expert opinion on drug metabolism & toxicology.

[39]  M. Negishi,et al.  IDENTIFICATION OF HMG-CoA REDUCTASE INHIBITORS AS ACTIVATORS FOR HUMAN, MOUSE AND RAT CONSTITUTIVE ANDROSTANE RECEPTOR , 2005, Drug Metabolism and Disposition.

[40]  C. Bisgaier,et al.  Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. , 1998, Atherosclerosis.

[41]  M Schwab,et al.  UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo , 2010, Clinical pharmacology and therapeutics.

[42]  H. Cai,et al.  Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[43]  Jan G. Hengstler,et al.  The Holy Grail of Hepatocyte Culturing and Therapeutic Use , 2009 .

[44]  S. Numazawa,et al.  A physiological role of AMP-activated protein kinase in phenobarbital-mediated constitutive androstane receptor activation and CYP2B induction. , 2007, The Biochemical journal.

[45]  Rosario,et al.  Statin regulation of CYP 3 A 4 and CYP 3 A 5 expression CYP 3 A 4 & CYP 3 A 5 : function & variants , 2009 .

[46]  P. Neuvonen,et al.  Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.

[47]  H. Glaeser,et al.  Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine* , 2002, The Journal of Biological Chemistry.

[48]  P. Neuvonen,et al.  Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites , 2005, Clinical pharmacology and therapeutics.

[49]  P. Neuvonen,et al.  ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin , 2008, Clinical pharmacology and therapeutics.

[50]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.